Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice.
The protective efficacy of mucosal immunization with purified respiratory syncytial virus (RSV) fusion protein (F) using cholera toxin (CT) as an adjuvant was assessed in mice. Intranasal vaccination with F+CT induced F-specific serum IgG and nasal IgA and resulted in 75% protection from nasal virus replication compared with control mice. Intranasal CT+F with simultaneous parenteral F provided complete protection equivalent to intranasal live virus immunization.
Walsh
E E
EE
Department of Medicine, Rochester General Hospital, NY.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000287:Administration, Topical; D000818:Animals; D002772:Cholera Toxin / Q000276:immunology; D005260:Female; D015707:HN Protein; D007114:Immunization; D046911:Macromolecular Substances; D008297:Male; D051379:Mice; D008954:Models, Biological; D009297:Nasal Mucosa / Q000276:immunology / Q000382:microbiology; D012136:Respiratory Syncytial Viruses / Q000276:immunology* / Q000502:physiology; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
D000276:Adjuvants, Immunologic; D015707:HN Protein; D046911:Macromolecular Substances; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins; D014764:Viral Proteins; D014765:Viral Vaccines; C116204:attachment protein G; D002772:Cholera Toxin